Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 41.1% in January

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the target of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 8,600 shares, a decrease of 41.1% from the January 15th total of 14,600 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 35,300 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Artelo Biosciences in a research note on Monday, December 9th. LADENBURG THALM/SH SH upgraded Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Artelo Biosciences in a report on Tuesday, January 14th.

Artelo Biosciences Trading Down 14.4 %

ARTL opened at $1.19 on Friday. Artelo Biosciences has a one year low of $0.91 and a one year high of $1.73. The business’s 50-day simple moving average is $1.15 and its 200-day simple moving average is $1.17.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. On average, sell-side analysts anticipate that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.